Dr. Dholaria on the Rationale for the MagnetisMM-1 Trial in Multiple Myeloma

Bhagirathbhai Dholaria, MBBS, assistant professor of medicine, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses the rationale for the phase 1 MagnetisMM-1 trial (NCT03269136) in relapsed/refractory multiple myeloma.

Novel therapies are needed to improve outcomes for patients with relapsed/refractory multiple myeloma, Dholaria explains. The MagnetisMM-1 study evaluated the safety and efficacy of the novel bispecific antibody elranatamab (PF-06863135) alone and in combination with immunomodulatory agents, such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), in patients with relapsed/refractory multiple myeloma.

Currently, the data are not mature enough to draw conclusions as to whether elranatamab stands out among other BCMA-directed bispecific antibodies being evaluated in similar ongoing clinical trials, Dholaria explains. Many of these agents have demonstrated efficacy, as well as tolerability, among patients with relapsed/refractory multiple myeloma.

Elranatamab is being evaluated as a single agent in the ongoing phase 2 MagnetisMM-3 trial (NCT04649359).